Equine CYP2B6: genomic annotation, heterologous expression and its role in the metabolism of ketamine

被引：0
|
作者：
Schmitz, A. [1 ]
Peters, L. [2 ]
Demmel, S. [2 ]
Haase, B. [3 ]
Buters, J. [4 ]
Thormann, W. [5 ]
Leeb, T. [3 ]
Mevissen, M. [2 ]
机构：
[1] Univ Bern, Bern, Switzerland
[2] Uni Bern, Vetsuisse Fac, Div Vet Pharmacol & Toxicol, Bern, Switzerland
[3] Uni Bern, Vetsuisse Fac, Inst Genet, Bern, Switzerland
[4] Tech Univ Munich, Helmholtz Zentrum Munchen, ZAUM Ctr Allergy & Environm, Munich, Germany
[5] Uni Bern, Inst Infect Dis, Clin Pharmacol Lab, Bern, Switzerland
来源：
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [21] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [22] INFLUENCE OF CYP2B6*6 GENOTYPE ON BUPROPION ENANTIOMERS METABOLISM AND CLEARANCE
    Kharasch, E. D.
    Crafford, A.
    Parchomski, J.
    Blood, J.
    Regina, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S54 - S54
  • [23] Human CYP2B6: expression, inducibility and catalytic activities
    Gervot, L
    Rochat, B
    Gautier, JC
    Bohnenstengel, F
    Kroemer, H
    de Berardinis, V
    Martin, H
    Beaune, P
    de Waziers, I
    PHARMACOGENETICS, 1999, 9 (03): : 295 - 306
  • [24] Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
    H-J Xie
    Ü Yasar
    S Lundgren
    L Griskevicius
    Y Terelius
    M Hassan
    A Rane
    The Pharmacogenomics Journal, 2003, 3 : 53 - 61
  • [25] Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry
    Wang, Pan-Fen
    Neiner, Alicia
    Kharasch, Evan D.
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (10) : 1195 - 1205
  • [26] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [27] Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
    Xie, HJ
    Yasar, Ü
    Lundgren, S
    Griskevicius, L
    Terelius, Y
    Hassan, M
    Rane, A
    PHARMACOGENOMICS JOURNAL, 2003, 3 (01): : 53 - 61
  • [28] Role of polyphorphic human CYP2B6 in cyclophosphamide bioactivation
    Xie, HJ
    Yasar, Ü
    Lundgren, S
    Griskevicius, L
    Terelius, Y
    Hassan, M
    Rane, A
    DRUG METABOLISM REVIEWS, 2003, 35 : 129 - 129
  • [29] Novel CYP2B6 polymorphisms and their impact on efavirenz and bupropion metabolism
    Klein, K.
    Radloff, R.
    Gras, A.
    Masquelier, C.
    Arumugam, K.
    Karasi, J-C
    Seguin-Devaux, C.
    Zanger, U. M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S41 - S41
  • [30] Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
    Desta, Zeruesenay
    Saussele, Tanja
    Ward, Bryan
    Blievernicht, Julia
    Li, Lang
    Klein, Kathrin
    Flockhart, DavidA
    Zanger, Ulrich M.
    PHARMACOGENOMICS, 2007, 8 (06) : 547 - 558
12345